Overview

Osteoarthritis Therapeutics Market is poised to value over USD 12.1 billion by 2027 end at a CAGR of over 8.6% during the forecast period 2020 to 2027.

The rising obese and geriatric population and increas in the number of patients diagnosed with osteoarthritis are some major factors responsible for the proliferation of the market.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Osteoarthritis Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Osteoarthritis Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Osteoarthritis Therapeutics Market:

• Sanofi
• Horizon Therapeutics PLC
• Johnson & Johnson
• Glaxosmithkline PLC
• Bayer AG
• Abbott
• Pfizer, Inc.
• Eli Lilly
• Anika Therapeutics, Inc.
• Novartis
• Ferring Pharmaceuticals
• Bioventus
• Zimmer Biomet Holdings, Inc.
• Fidia Farmaceutici S.P.A.
• Flexion Therapeutics, Inc.

 (Note: The list of the major players will be updated with the latest market scenario and trends)

Osteoarthritis Therapeutics Market Segmentation:

By Anatomy

• Knee
• Hip
• Hand
• Small Joints (Foot & Ankle and Wrist)

By Drug Type

• Viscosupplementation Agents
• Nonsteroidal Anti-inflammatory Drugs
  o Naproxen
  o Aspirin
  o Diclofenac
  o Ibuprofen
  o Other NSAIDs
• Analgesics
  o Duloxetine
  o Acetaminophen
• Corticosteroids

By Route of Administration

• Parenteral
• Topical
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Purchasing Pattern

• Prescription Drug
• Over-the-counter Drug

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Osteoarthritis Therapeutics Market By Anatomy, By Drug Type, By Route of Administration, By Distribution Channel, By Purchasing Pattern and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
          1.1 Objectives of the Study 
          1.2 Market Definition 
          1.3 Market Scope 
               1.3.1 Years Considered for the Study
               1.3.2 Market Covered
          1.4 Currency 
          1.5 Limitations 
          1.6 Stakeholders 

2.  Research Methodology 
          2.1 Research Data 
              2.1.1 Secondary Data
                     2.1.1.1 Key Data from Secondary Sources
              2.1.2 Primary Data
                     2.1.2.1 Key Data from Primary Sources
          2.2 Market Size Estimation 
          2.3 Market Breakdown and Data Triangulation 
          2.4 Assumptions for the Study  

3. Executive Summary
          3.1 Market Outlook
          3.2 Segment Outlook
          3.3 Competitive Insights

4. Global Osteoarthritis Therapeutics Market Variables, Trends & Scope
          4.1. Market Lineage Outlook
          4.2. Penetration and Growth Prospect Mapping
          4.3. Industry Value Chain Analysis
          4.4. Cost Analysis Breakdown
          4.5. Technology Overview
          4.6. Regulatory Framework
                4.6.1. Reimbursement Framework
                4.6.2. Standards and Compliances

5. Market Overview
          5.1. Market Dynamics
                5.1.1. Market Driver Analysis
                         5.1.1.1. Increasing focus of Osteoarthritis Therapeutics Companies on Brand Protection
                         5.1.1.2. Untapped Opportunities in Emerging Regions
                5.1.2. Market Restraint Analysis
                         5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                5.1.3. Industry Challenges
                         5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Osteoarthritis Therapeutics Market Analysis Tools

         6.1. Industry Analysis - Porter’s
                6.1.1. Supplier Power
                6.1.2. Buyer Power
                6.1.3. Substitution Threat
                6.1.4. Threat from New Entrants
                6.1.5. Competitive Rivalry
         6.2. Pestel Analysis
                6.2.1. Political Landscape
                6.2.2. Environmental Landscape
                 6.2.3. Social Landscape
                6.2.4. Technology Landscape
                6.2.5. Legal Landscape
         6.3. Major Deals And Strategic Alliances Analysis
               6.3.1. Joint Ventures
               6.3.2. Mergers and Acquisitions
               6.3.3. Licensing and Partnership
               6.3.4. Technology Collaborations
               6.3.5. Strategic Divestments
         6.4. Market Entry Strategies
         6.5. Case Studies

7. Global Osteoarthritis Therapeutics Market, By Anatomy Historical Analysis and Forecast 2020-2027 (USD Million)
         7.1. Knee
         7.2. Hip
         7.3. Hand
         7.4. Small Joints (Foot & Ankle and Wrist)

8. Global Osteoarthritis Therapeutics Market, By Drug Type Historical Analysis and Forecast 2020-2027 (USD Million)
         8.1. Viscosupplementation Agents
         8.2. Nonsteroidal Anti-inflammatory Drugs
               8.2.1. Naproxen
               8.2.2. Aspirin
               8.2.3. Diclofenac
               8.2.4. Ibuprofen
               8.2.5. Other NSAIDs
         8.3. Analgesics
               8.3.1. Duloxetine
               8.3.2. Acetaminophen
         8.4. Corticosteroids

9. Global Osteoarthritis Therapeutics Market, By Route of Administration Historical Analysis and Forecast 2020-2027 (USD Million)
         9.1. Parenteral
         9.2. Topical
         9.3. Oral 

10. Global Osteoarthritis Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million)
       10.1. Hospital Pharmacies
       10.2. Retail Pharmacies
       10.3. Online Pharmacies

11. Global Osteoarthritis Therapeutics Market, By Purchasing Pattern Historical Analysis and Forecast 2020-2027 (USD Million)
       11.1. Prescription Drug
       11.2. Over-the-counter Drug

12.  North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       12.1. Introduction
       12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
              12.2.1. U.S.A
              12.2.2. Canada
              12.2.3. Mexico
       12.3. Market Size (USD Million) Forecast for North America 2020-2027

13. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       13.1. Introduction
       13.2. Regional Market Trends
       13.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
              13.3.1. Brazil
              13.3.2. Venezuela
              13.3.3. Argentina
              13.3.4. Rest of Latin America
       13.4. Market Size (USD Million) Forecast for Latin America 2020-2027

14. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       14.1. Introduction
       14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
              14.2.1. Germany
              14.2.2. U.K
              14.2.3. France
              14.2.4. Italy
              14.2.5. Spain
              14.2.6. Russia
              14.2.7. Poland
              14.2.8. Switzerland
              14.2.9. Rest of Western Europe

15. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       15.1. Introduction
       15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
              15.2.1. Japan
              15.2.2. China
              15.2.3. Singapore
              15.2.4. India
              15.2.5. Australia and New Zealand
              15.2.6. ASEAN
              15.2.7. South Korea
              15.2.8. Rest of Asia Pacific
       15.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027

16. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       16.1. Introduction
       16.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
              16.2.1. Saudi Arabia
              16.2.2. UAE
              16.2.3. South Africa
              16.2.4. Egypt
       16.3. Market Size (USD Million) Forecast for MEA 2020-2027

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Technology Portfolio, Financial Layouts)
       17.1. Sanofi
                17.1.1. Company Overview
                17.1.2. Product Portfolio
                17.1.3. SWOT Analysis
                17.1.4. Financial Overview
                17.1.5. Strategic Overview
       17.2. Horizon Therapeutics PLC
                17.2.1. Company Overview
                17.2.2. Product Portfolio
                17.2.3. SWOT Analysis
                17.2.4. Financial Overview
                17.2.5. Strategic Overview
       17.3. Johnson & Johnson
                17.3.1. Company Overview
                17.3.2. Product Portfolio
                17.3.3. SWOT Analysis
                17.3.4. Financial Overview
                17.3.5. Strategic Overview
       17.4. Glaxosmithkline PLC
                17.4.1. Company Overview
                17.4.2. Product Portfolio
                17.4.3. SWOT Analysis
                17.4.4. Financial Overview
                17.4.5. Strategic Overview
       17.5. Bayer AG
                17.5.1. Company Overview
                17.5.2. Product Portfolio
                17.5.3. SWOT Analysis
                17.5.4. Financial Overview
                17.5.5. Strategic Overview
       17.6. Abbott
                17.6.1. Company Overview
                17.6.2. Product Portfolio
                17.6.3. SWOT Analysis
                17.6.4. Financial Overview
                17.6.5. Strategic Overview
       17.7. Pfizer, Inc.
                17.7.1. Company Overview
                17.7.2. Product Portfolio
                17.7.3. SWOT Analysis
                17.7.4. Financial Overview
                17.7.5. Strategic Overview
       17.8. Eli Lilly
                17.8.1. Company Overview
                17.8.2. Product Portfolio
                17.8.3. SWOT Analysis
                17.8.4. Financial Overview
                17.8.5. Strategic Overview
       17.9. Anika Therapeutics, Inc.
                17.9.1. Company Overview
                17.9.2. Product Portfolio
                17.9.3. SWOT Analysis
                17.9.4. Financial Overview
                17.9.5. Strategic Overview
       17.10. Novartis
                17.10.1. Company Overview
                17.10.2. Product Portfolio
                17.10.3. SWOT Analysis
                17.10.4. Financial Overview
                17.10.5. Strategic Overview
       17.11. Ferring Pharmaceuticals
                17.11.1. Company Overview
                17.11.2. Product Portfolio
                17.11.3. SWOT Analysis
                17.11.4. Financial Overview
                17.11.5. Strategic Overview
       17.12. Bioventus
                17.12.1. Company Overview
                17.12.2. Product Portfolio
                17.12.3. SWOT Analysis
                17.12.4. Financial Overview
                17.12.5. Strategic Overview
       17.13. Zimmer Biomet Holdings, Inc.
                17.13.1. Company Overview
                17.13.2. Product Portfolio
                17.13.3. SWOT Analysis
                17.13.4. Financial Overview
                17.13.5. Strategic Overview
       17.14. Fidia Farmaceutici S.P.A.
                17.14.1. Company Overview
                17.14.2. Product Portfolio
                17.14.3. SWOT Analysis
                17.14.4. Financial Overview
                17.14.5. Strategic Overview
       17.15. Flexion Therapeutics, Inc.
                17.15.1. Company Overview
                17.15.2. Product Portfolio
                17.15.3. SWOT Analysis
                17.15.4. Financial Overview
                17.15.5. Strategic Overview

18. FutureWise SME key takeaway points for Client

Tables

Figures